<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141087">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01717183</url>
  </required_header>
  <id_info>
    <org_study_id>FI-12-05-310 3113</org_study_id>
    <nct_id>NCT01717183</nct_id>
  </id_info>
  <brief_title>Assessment of the Efficacy and Safety of a New Wound Dressing in the Local Treatment of Diabetic Foot Ulcers</brief_title>
  <official_title>Assessment of the Efficacy and Safety of a New Wound Dressing in the Local Treatment of Diabetic Foot Ulcers: a Prospective, Randomised, Controlled, Double-blind, European Multicentre Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires URGO</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires URGO</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>United Kingdom: National Health Service</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this trial is to demonstrate that the new dressing is more effective
      than the current dressing in the local treatment of chronic foot ulcers in diabetic
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of complete wound closure</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to complete wound closure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in wound surface area</measure>
  </secondary_outcome>
  <condition>Diabetic Foot Ulcer(s)</condition>
  <arm_group>
    <arm_group_label>URGO 310 3113 dressing - new</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>flexible, conformable, non-adhesive and non-occlusive lipido-colloid matrix that does not adhere to the wound.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>URGO 310 3113 dressing</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>flexible, conformable, non-adhesive and non-occlusive lipido-colloid matrix that does not adhere to the wound.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Urgo 310 3113</intervention_name>
    <description>URGO 310 3113 dressing may be changed every 2 to 4 days, and left in place for up to 7 days, depending on the level of exudate and the wound condition</description>
    <arm_group_label>URGO 310 3113 dressing - new</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo URGO 310 3113 dressing</intervention_name>
    <arm_group_label>URGO 310 3113 dressing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female over 18 years old who has provided his/her written informed consent

          -  Patient covered by the French national insurance system

          -  Patient with Type 1 or Type 2 diabetes mellitus with glycated hemoglobi(HbA1c) levels
             ≤ 10% (assayed in the previous 3 months. If not available, this assay must be
             performed during the run-in period)

          -  Inpatient or outpatient who can be monitored by the same investigating team
             throughout the duration of the study

          -  Patient who agrees to wear the prescribed off-loading system every day, associated
             with the test dressing

          -  DFU with adequate arterial blood supply in the target limb DFU grade I-C or II-C as
             defined by the University of Texas Diabetic Wound Classification

          -  Neuropathy confirmed by loss of protective sensation to monofilament test
             (Semmes-Weinstein 5.07 monofilament)

          -  DFU located on the toe or on the lateral, dorsal or plantar side of the foot

          -  Target DFU surface area between 1 cm² and 30 cm², following debridement DFU duration
             between 1 and 24 months

          -  No local clinical infection (as defined by IDSA/IWGDF criteria) for any wound (target
             DFU or not) on lower limbs

          -  DFU adequately debrided

        Exclusion Criteria:

          -  Pregnant or breast-feeding woman or woman of childbearing potential not using
             effective means of contraception

          -  Patient who took part in another clinical trial in the previous month or who is to
             take part in another clinical trial in the 20 weeks following inclusion

          -  Patient with any known intolerance or allergy or reported adverse reaction to one of
             the components of the trial dressings

          -  Patient who has undergone surgery or surgical revascularization (vascular
             reconstruction or angioplasty) in the previous 2 months

          -  Patient who has presented an acute ischemic event (Acute Myocardial Infarction (AMI)
             or stroke) in the 3 months before inclusion

          -  Patient with Severe kidney failure, defined as requirement for dialysis

          -  Patient with a systemic infection not controlled by suitable antibiotic treatment

          -  Patient with known osteomyelitis

          -  Patient with leg ulcer(s), regardless of limb

          -  Patient with wounds other than the target DFU located on the heel or on the
             interdigital part of the foot

          -  Patient with an active neoplastic condition, treated by radiotherapy, chemotherapy,
             hormone therapy or immunosuppressant agents

          -  Patient treated for a chronic disease requiring high doses of systemic
             corticosteroids (≥ 40 mg.d-1 of prednisolone or equivalent)

          -  Patient with a severe illness that might lead to premature withdrawal from the trial

          -  DFU for which surgery or surgical revascularization is planned at any time during the
             study

          -  Deep DFU defined as stage III or IV (University of Texas Diabetic Wound
             Classification)

          -  DFU clinically infected as defined by IDSA/IWGDF criteria

          -  DFU with more than 20% of its surface area covered by black necrotic tissue following
             debridement

          -  DFU located on an amputation stump

          -  DFU with neoplastic component
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jacques MARTINI, MD</last_name>
    <phone>00 33 5 61 32 32 89</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques MARTINI, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>October 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patient</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
